Takis is coordinating the project REVER3MAB, in collaboration with Istituto Regina Elena IRCCS and IBI – Istituto Biochimico Lorenzini, for the development of an anticancer monoclonal antibody aimed at "reverting" resistance to conventional oncological therapies.

The acronym "REVER3MAB" identifies a monoclonal antibody, directed against the ErbB3 protein able to block the proliferation of tumor cells in vitro and in vivo, with potential use as a therapeutic agent in the clinic.
Goals of the project are the optimization of the drug for clinical experimentation, its production on industrial scale and the setting-up of widely applicable humanized tumor models, the ImmunoAvatars. Counting on our expertise, we really expect to make a difference in the lives of cancer patients.